After a hiring blitz, where is Mustang's CAR-T manufacturing headed?

Until recently, New York's Mustang Bio has focused its business exclusively on cell therapies. Earlier this week, the biotech announced plans to license an ex vivo lentiviral gene therapy developed at St. Jude Children’s Research Hospital for the treatment of a rare illness known as XSCID, otherwise known as bubble boy disease.